258 related articles for article (PubMed ID: 20888390)
1. Aromatase, estrone sulfatase, and 17β-hydroxysteroid dehydrogenase: structure-function studies and inhibitor development.
Hong Y; Chen S
Mol Cell Endocrinol; 2011 Jul; 340(2):120-6. PubMed ID: 20888390
[TBL] [Abstract][Full Text] [Related]
2. The selective estrogen enzyme modulator (SEEM) in breast cancer.
Chetrite GS; Pasqualini JR
J Steroid Biochem Mol Biol; 2001; 76(1-5):95-104. PubMed ID: 11384867
[TBL] [Abstract][Full Text] [Related]
3. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
Chetrite GS; Thole HH; Philippe JC; Pasqualini JR
Anticancer Res; 2004; 24(3a):1433-8. PubMed ID: 15274306
[TBL] [Abstract][Full Text] [Related]
4. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
5. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids.
Le Bail JC; Laroche T; Marre-Fournier F; Habrioux G
Cancer Lett; 1998 Nov; 133(1):101-6. PubMed ID: 9929167
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
7. Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities.
Le Bail JC; Pouget C; Fagnere C; Basly JP; Chulia AJ; Habrioux G
Life Sci; 2001 Jan; 68(7):751-61. PubMed ID: 11205867
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
9. Reductive 17beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer.
Aka JA; Mazumdar M; Lin SX
Mol Cell Endocrinol; 2009 Mar; 301(1-2):183-90. PubMed ID: 19038308
[TBL] [Abstract][Full Text] [Related]
10. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
14. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
15. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
[TBL] [Abstract][Full Text] [Related]
16. Estradiol as an anti-aromatase agent in human breast cancer cells.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):12-7. PubMed ID: 16413774
[TBL] [Abstract][Full Text] [Related]
17. The SEEM: selective estrogen enzyme modulators in breast cancer.
Pasqualini JR; Ebert C; Chetrite GS
Gynecol Endocrinol; 1999 Dec; 13 Suppl 6():1-8. PubMed ID: 10862262
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens.
Santner SJ; Santen RJ
J Steroid Biochem Mol Biol; 1993 May; 45(5):383-90. PubMed ID: 8388710
[TBL] [Abstract][Full Text] [Related]
20. The selective estrogen enzyme modulators in breast cancer: a review.
Pasqualini JR
Biochim Biophys Acta; 2004 Jun; 1654(2):123-43. PubMed ID: 15172700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]